1. Home
  2. TSLX vs EVO Comparison

TSLX vs EVO Comparison

Compare TSLX & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sixth Street Specialty Lending Inc.

TSLX

Sixth Street Specialty Lending Inc.

N/A

Current Price

$21.84

Market Cap

2.2B

Sector

Finance

ML Signal

N/A

Logo Evotec SE

EVO

Evotec SE

N/A

Current Price

$2.98

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TSLX
EVO
Founded
2010
1993
Country
United States
Germany
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.1B
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
TSLX
EVO
Price
$21.84
$2.98
Analyst Decision
Buy
Strong Buy
Analyst Count
10
1
Target Price
$23.50
$7.00
AVG Volume (30 Days)
428.2K
115.9K
Earning Date
11-04-2025
11-05-2025
Dividend Yield
9.37%
N/A
EPS Growth
N/A
N/A
EPS
2.04
N/A
Revenue
$464,512,000.00
$887,396,457.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$8.80
P/E Ratio
$10.71
N/A
Revenue Growth
N/A
N/A
52 Week Low
$18.58
$2.84
52 Week High
$25.17
$5.10

Technical Indicators

Market Signals
Indicator
TSLX
EVO
Relative Strength Index (RSI) 47.34 40.48
Support Level $21.62 $2.94
Resistance Level $22.83 $3.09
Average True Range (ATR) 0.28 0.09
MACD -0.01 0.01
Stochastic Oscillator 18.85 24.49

Price Performance

Historical Comparison
TSLX
EVO

About TSLX Sixth Street Specialty Lending Inc.

Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: